Month: December 2020

Attached your will find information about payments for Havi04 and Havi07 on duedate 30.12.20This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Vedlagt informasjon om betalinger som blir foretatt på forfallsdag 30.12.20Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12VedleggHavi04 Q420Havi07 Q420

Company Announcement16 December 2020Announcement No. 31Transactions of executives and related parties in NKT sharesAccording to the Market Abuse Regulation art. 19 NKT announces to have received notification regarding acquisition of NKT shares as follows:ContactInvestor Relations:    Michael Nass Nielsen, Head of Investor Relations, Tel.: +45 2494 1654Press:                           Helle Gudiksen, Head of Group Communications, Tel.: +45 2349 9098AttachmentTransactions of executives and related parties in NKT shares_31

Selskabsmeddelelse16. december 2020Meddelelse nr. 31 Ledende medarbejderes og disses nærtståendes handel med NKT aktierKontaktInvestor Relations:    Michael Nass Nielsen, Head of Investor Relations, tlf.: +45 2494 1654Presse:                         Helle Gudiksen, Head of Group Communications, tlf.: +45 2349 9098Vedhæftet filLedende medarbejderes og disses nærtståendes handel med NKT aktier_31

Talenom Oyj    Pörssitiedote    16.12.2020 klo 9.40Talenom Oyj:n tulosjulkistukset ja varsinainen yhtiökokous vuonna 2021

Talenom Plc, Stock exchange release, 16 December 2020 at 9:40 EETIn addition, Talenom will publish a Half-year report and two Business Reviews in 2021:Business Review for January-March on Monday, 26 April 2021Half-year report for January-June on Monday, 2 August 2021Business Review for January-September on Monday, 1 November 2021The reports will be published at approximately 13:30 Finnish time. The reports are available on the company’s website www.talenom.fi/en/investors immediately after publication.TALENOM PLCBOARD OF DIRECTORSFurther information:Otto-Pekka HuhtalaCEO, Talenom Plc+358 40 7038 554otto-pekka.huhtala@talenom.fiTalenom Plc is an accounting firm established in 1972. Talenom offers a wide range of accounting services as well as other expert and advisory services to support its clients’ business. The company has its own software...

Press releaseDecember 16, 2020Appointments to Edenred’s Executive CommitteeJulien Tanguy appointed Executive Vice President, FinanceEric Sauvage appointed Executive Vice President, Marketing & StrategyJulien Tanguy, previously Chief Executive Officer of Edenred France, has been appointed Group Executive Vice President, Finance and joined the Edenred Group Executive Committee.A graduate of SKEMA Business School, Julien Tanguy, 48, began his career in 1996 as an auditor at PricewaterhouseCoopers. In 2001, he joined SFR as Controlling Manager and subsequently moved to Europcar in 2005, where he served successively as Finance Director at Europcar Information Services and Chief Financial Officer of Europcar France. In 2011, he joined Edenred France as Chief Financial Officer, also taking on the role of Operations Director one year later....

Communiqué de presse16 décembre 2020Nominations au sein du Comité exécutif d’EdenredJulien Tanguy est nommé Directeur général FinanceEric Sauvage est nommé Directeur général Marketing et StratégieJulien Tanguy, précédemment Directeur général d’Edenred France, est nommé Directeur général Finance du Groupe et intègre le Comité exécutif du Groupe.Diplômé de SKEMA Business School, Julien Tanguy est âgé de 48 ans. Il débute sa carrière en 1996 en tant qu’auditeur chez PricewaterhouseCoopers. En 2001, il devient  Controlling Manager chez SFR. Il intègre Europcar en 2005, où il occupe successivement les fonctions de Directeur Financier d’Europcar Information Services puis Directeur Financier d’Europcar France. En 2011, il rejoint Edenred France comme Directeur Financier, fonction qu’il cumule avec celle de Directeur des Opérations un an plus tard....

PARIS and NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs acting directly on the brain to treat difficult-to-treat / resistant hypertension and heart failure, announces today that it has signed a strategic contract with Delpharm for the manufacture of the next clinical batches of firibastat tablets on an industrial scale and the establishment of production lines for future commercial batches.The efficacy of firibastat, the first drug-candidate of the class of brain aminopeptidase A inhibitors, is currently being evaluated in an international phase III clinical trial (FRESH study) in uncontrolled hypertensive patients despite a treatment comprising at least two classes of antihypertensive...

PRESS RELEASEDecember 16, 2020Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the reduction of its ownership stake in Scandion Oncology A/S (Spotlight Stock Market: SCOL) below 5%. This reduction is a result of a rights issue completed by Scandion Oncology on December 15, 2020.Scandion Oncology was formed in 2017 through a spin-out of assets from Saniona. These assets included SCO-101, a first-in-class molecule targeting chemotherapy resistance, as well as related analogues and technical expertise.For more information, please contactTrista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.comThe information was submitted for publication, through the agency of the contact person set out above, at 8:00 CET on December 16,...